12 results
In this study, we aim to improve recognition of delirium in a palliative care population with advancedcancer and we aim to provide evidence for optimal treatment of delirium through adequate dosing ofpreferred neuroleptic.Primary objectives:1) To…
To evaluate whether preventive treament with haloperidol lowers the risk for delirium in stroke patients with an increased risk for delirium.
The current study is designed as a first exploration of this model. The hypothesis is that haloperidol will lead to an amelioration of the *psychotomimetic* effects of the THC-challenge.
The primary objective of this study is to test the hypothesis that discontinuation of antipsychotics does not lead to deterioration in functioning as measured by the ABC.
To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.
The purpose of this study is to investigate the role of dopamine in learning about sexual reward in healthy females. We suppose that repeated associations between a neutral stimulus and sexual stimulation results, through classical conditioning, in…
The primary study objective is to determine whether Febuxostat daily 80-120 mg is better than Allopurinol daily 100-600 mg in inducing positive changes in Pulse Wave Velocity (PWV) after 36 weeks of treatment.
To obtain a nonlinear mixed effects model (NONMEM) describing the population pharmacokinetics of haloperidol in the central (CSF) and peripheral compartment after oral and intravenous injection.
Primary objective:- To assess safety, efficacy, and potentially select the most active treatment regimen among 3 treatment arms to advance to the Phase 3 component of the study.Secondary objectives:- Ph1b: evaluate PK & assess immunogenicity…
Objectives for Part A1 Monotherapy Dose EscalationPrimary Objective:* To assess safety, and tolerability at increasing dose levels of PF 04518600 in patients with selected advanced or metastatic solid tumors in order to establish the MTD.Secondary…
To test whether the proportion of patients in remission during the last 6 months of follow up is higher for a T2T strategy compared to a T2S stop strategy.
The GO TEST OVERTURE study aims to demonstrate the superiority of the Treat to Target management strategy over a Treat to Avoid Symptoms approach in terms of clinical remission of gout symptoms.